logo-loader
viewCynata Therapeutics Ltd

Cynata Therapeutics: Access latest PPT from Proactive's CEO Sessions

Snapshot

Dr Ross Macdonald talked stemcell research with investors.

Cynata-CEO-Dr-Ross-Macdonald-presenting-Syd-Mar-2017.jpg

Quick facts: Cynata Therapeutics Ltd

Price: 0.62 AUD

ASX:CYP
Market: ASX
Market Cap: $72.62 m
Follow

Cynata Therapeutics' (ASX:CYP) CEO, Dr Ross Macdonald, joined Proactive's CEO Sessions in Sydney on Tuesday 14th March and Melbourne on Wednesday 15th March.

Cynata is now in a transition to a clinical stage company, with the focus on stem cells and regenerative medicine.

Earlier this year Cynata announced a breakthrough strategic partnership with Fujifilm which included the Japanese company investing in the company to become the largest shareholder.

 

ACCESS THE FULL PRESENTATION HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cynata Therapeutics Ltd named herein, including the promotion by the Company of Cynata Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Cynata Therapeutics meets with New York investors following good news from...

Cynata Therapeutics Ltd (ASX:CYP) (OTCMKTS:CYYNF) CEO Ross Macdonald tells Proactive's Christine Corrado the cell therapy company has met the clinical endpoints of a Phase 1 trial of its Cymerus mesenchymal stem cell (MSC) product candidate in people with steroid-resistant acute...

on 09/10/2018

2 min read